

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 June 2001 (07.06.2001)


PCT

(10) International Publication Number
WO 01/40802 A3

- (51) International Patent Classification⁷: **G01N 33/68**, C07K 14/72
- (21) International Application Number: PCT/GB00/04606
- (22) International Filing Date: 1 December 2000 (01.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
9928539.7 2 December 1999 (02.12.1999) GB
0012699.5 24 May 2000 (24.05.2000) GB
- (71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **COUSENS, Diane, Joan** [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **IGNAR, Diane, Michele** [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). **SANSEAU, Philippe** [FR/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **VOLPE, Filippo** [IT/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).
- (74) Agent: **REES, Marion, L.**; GlaxoSmithKline, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
21 February 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL PROTEIN

LTRGW1 enhances BLTR (5ug) response in a dose dependent manner.



(57) Abstract: A method for the identification of a compound which modulates leukotriene B4 like (LTRGW1) receptor activity comprises contacting an LTRGW1 polypeptide comprising (i) The amino acid sequence of SEQ ID #2, or (ii) A variant of (i) which is capable of binding leukotrienes; or (iii) A fragment of (i) or (ii) which is capable of binding leukotrienes. Additionally, LTRGW1 has been determined to enhance the response of the leukotriene B4 Receptor (BLTR) to LTB4. Hence LTRGW1 may be used in methods to identify compounds which modulate BLTR receptor activity.

WO 01/40802 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04606

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/68 C07K14/72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, PAJ, WPI Data, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 42484 A (SMITHKLINE BEECHAM CORP) 26 August 1999 (1999-08-26) page 19, line 14 - line 17 page 6, line 18 - line 29 page 34, line 1 -page 35, line 2 claims 1,4,6-8	12, 17-20, 24-26
Y P,X	& DATABASE EMBL 'Online! ID/Acc.No. : AAY57456, 25 February 2000 (2000-02-25) ELSHOURBAGY, N ET AL.: "A new G-protein coupled receptor, Fishboy used to treat, e.g. benign prostatic hypertrophy" XP002170530 the whole document --- -/--	1-5 12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

28 June 2001

Date of mailing of the international search report

12/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Tuynman, A

INTERNATIONAL SEARCH REPORT

ernational Application No

PCT/GB 00/04606

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
Y	JACKSON R H ET AL: "COMPARISON OF ANTAGONIST AND AGONIST BINDING TO THE LEUKOTRIENE B-4 RECEPTOR ON INTACT HUMAN POLYMORPHONUCLEAR NEUTROPHILS PMN" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 262, no. 1, 1992, pages 80-89, XP001011803 ISSN: 0022-3565 abstract	1-5
A	WIELAND THOMAS ET AL: "Measurement of receptor-stimulated guanosine 5'-O-(gamma-thio)triphosphate binding by G proteins." METHODS IN ENZYMOLOGY, vol. 237, 1994, pages 3-13, XP000197101 1994 Academic Press, Inc.; Academic Press Ltd. 1250 Sixth Ave., San Diego, California 92101, USA; 14 Belgrave Square, 24-28 Oval Road, London NW1 70X, England, UK ISBN: 0-12-182138-2 cited in the application the whole document	1,8-10
E	WO 01 19985 A (YOKOMIZO TAKEHIKO ;KATO KAZUHIKO (JP); SHIMIZU TAKAO (JP); ASAI KE) 22 March 2001 (2001-03-22) abstract	1-5,7-9, 12-26
T	& DATABASE EMBL 'Online! ID/Acc.No. : AAB73096, 5 June 2001 (2001-06-05) KATO, K. ET AL.: "Human leukotriene B4 receptor used in screening modifiers of its ligand binding for use in treatment of leukotriene B4-associated diseases" XP002170531 the whole document	

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04606

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 00 29423 A (LIU QINGYUN ;BAILEY WENDY J (US); MERCK & CO INC (US); WANG RUIPIN) 25 May 2000 (2000-05-25) page 9, line 6 -page 11, line 11 page 20, line 1 -page 21, line 8	6,12, 17-20, 24-26
A		1-5,9, 11,13-16 12
P,X	& DATABASE EMBL 'Online! ID/Acc.No. : AAY94477, 11 September 2000 (2000-09-11) LIU, Q. ET AL.: "Novel human polynucleotide encoding a G-protein coupled receptor, HG07, the agonist or antagonist of HG07 useful for treating disorders involving multiple sclerosis, or arthritis" XP002170532 abstract	
A	-----	6

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 12,17-21 relate to a compound or the use of this compound defined by reference to a desirable characteristic or property, namely being identifiable by a method according to any one of the claims 1-4,8 or 9-11.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds, having an amino acid sequence according to SEQ ID No 2,4,6 or 8.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04606

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9942484	A	26-08-1999	EP 1054903 A	29-11-2000
WO 0119985	A	22-03-2001	NONE	
WO 0029423	A	25-05-2000	NONE	